Andrew Perry
Corporate Officer/Principal chez G1 THERAPEUTICS, INC.
Fortune : 304 751 $ au 30/04/2024
Profil
Andrew Perry is currently the Chief Commercial Officer at G1 Therapeutics, Inc. He previously worked as the Vice President of US Marketing at ViiV Healthcare Ltd.
Mr. Perry is a graduate of the University of Glasgow and The University of Sheffield.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
G1 THERAPEUTICS, INC.
0,15% | 13/05/2024 | 78 951 ( 0,15% ) | 304 751 $ | 30/04/2024 |
Postes actifs de Andrew Perry
Sociétés | Poste | Début |
---|---|---|
G1 THERAPEUTICS, INC. | Corporate Officer/Principal | 02/08/2021 |
Anciens postes connus de Andrew Perry
Sociétés | Poste | Fin |
---|---|---|
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Andrew Perry
University of Glasgow | Graduate Degree |
The University of Sheffield | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
G1 THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Health Technology |